BeiGene
BGNE
#904
Rank
โ‚น1.859 T
Marketcap
โ‚น16,509
Share price
0.67%
Change (1 day)
5.46%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -โ‚น1,366

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -โ‚น1,405. In 2022 the company made an earnings per share (EPS) of -โ‚น1,635 a decrease over its 2021 EPS that were of -โ‚น1,284.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น1,366-16.49%
2022-โ‚น1,63527.35%
2021-โ‚น1,284-19.96%
2020-โ‚น1,60420.81%
2019-โ‚น1,32831.52%
2018-โ‚น1,010417.57%
2017-โ‚น195.07-37.16%
2016-โ‚น310.45158.95%
2015-โ‚น119.89

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น84.42-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น22.79-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA